BIO-Europe Spring® moves to Barcelona in March 2010 where Biocat, the BioRegion of Catalonia, promises to surprise business development executives with unexpected opportunities for projects, products and investments.
A long period of investment in Catalonia is today yielding the emergence of a biotechnology capability growing at a rapid rate of 20 new companies per year, and Read more »
BIO-Europe Spring® 2009 was in full swing on March 17 as 1,564 executives shifted into partnering high gear. The 233 meeting rooms reported 100 percent occupancy during the peak hour just after lunch. Before the day was over more than 3,500 one-to-one meetings took place.
The ground floor of the Milan Convention Centre was dedicated to Read more »
Large scale, late stage deals always steal the headlines and news of these agreements can move markets. Yet for business development executives at big pharma and venture capital firms, the real action is with upstream opportunities in meetings taking place at BIO-Europe Spring® 2009.
“Partnering starts with science scouts who are trolling their territories to find Read more »
EP Vantage’s interview with Bayhill’s CEO Mark Schwartz underscores the importance of striking strategic partnerships, and the role of partnering events like BIO-Europe Spring®, in helping promising biotechs make it through our tough economic climate:
It was supposed to have been one of the premier IPOs of 2008, forecast to raise around USD 86 million and Read more »
BIO-Europe Spring® welcomed the life science community back to a sunny Milan where the mood of executives seemed to perk up like flowers after what several called a long six months of doom and gloom for the industry.
Carola Schropp, President of EBD Group, welcomed 1,560 participants from 44 countries, a 15 percent increase over BIO-Europe Read more »
No one likes dancing with the bear, but for the moment it is still the bears who are leading the dance in biotech.
Throughout the panel discussions and workshops at BIO-Europe Spring® 2009 in Milan, biotech companies agreed no one needed another doom and gloom meeting about the current market conditions, and conference participants seemed Read more »
There remains a bright future for biotechnology in partnership with pharmaceutical companies, despite the current uncertainties about financing.
Shifting everyone’s focus forward at BIO-Europe Spring® and away from well-worn problems of conventional dealmaking was the morning session entitled “Personalized Medicine — The Next Big Thing in Biotech?”
The Vice Chairman for Investment Banking Europe with JP Morgan, Read more »
The charm and the challenge of Italy is keeping up with change. Even as you admire the venerable Duomo or da Vinci’s painting of The Last Supper, you step outside to discover the world’s greatest concentration of cutting edge fashion designers.
Unless you have recently revisited your views of biotechnology in Italy, there is a risk Read more »
Newsletter